ADELAIDE, Australia / RankWire.AI / – Australian scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute have pinpointed a novel molecular switch that influences the progression of aggressive tumors. Published in EMBO Molecular Medicine, this significant research uncovers a new potential approach to combat triple-negative breast cancer by restoring the activity of a vital regulatory molecule called miR-342. This breakthrough paves the way for strategies to prevent life-threatening secondary cancers in organs such as the lungs and bones.
Although triple-negative breast cancer represents 10% to 15% of Australia’s roughly 21,000 yearly breast cancer diagnoses, it accounts for a disproportionate share of fatalities. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, making standard hormone-targeted treatments ineffective. Researchers demonstrated that a decline in miR-342 leads to an overactive E2F pathway, which promotes the spread of dormant cancer cells throughout the body and the formation of dangerous secondary tumors.
Testing for Diagnostic Biomarkers Might Help Spot Patients Who Could Gain the Most
In pre-clinical experiments, scientists showed that increasing miR-342 levels considerably decreased the dissemination of cancer cells to distant organs. They also found that palbociclib, an approved CDK4/6 inhibitor used to treat hormone receptor-positive breast cancers, effectively suppressed metastatic tumor growth in models with low miR-342 expression. These results suggest that measuring miR-342 could enable clinicians to repurpose existing drugs for high-risk patient treatment.
Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology, co-senior author, affirmed that preventing metastasis remains the main hurdle in treating aggressive breast cancers. Gregory pointed out that because palbociclib targets the hyperactive E2F pathway, giving the drug after cancer spread can prevent microscopic deposits from growing. This approach shifts the focus from solely shrinking primary tumors to stopping microscopic secondary cancers from evolving into life-threatening conditions.
miR-342 as a Master Regulator of Cancer-Related Genes
The research team highlighted that the biological diversity of triple-negative breast cancer has historically hampered the development of universal targeted therapies. By identifying a specific biological vulnerability shared among a particular patient subgroup, this study opens opportunities for personalized treatment strategies. As Australian researchers develop a promising new method to address triple-negative breast cancer, efforts are underway to validate the findings using patient-derived models before progressing to clinical trials.
Medical oncologists and cancer research organizations throughout Australia expressed strong support for the findings, emphasizing the urgent need for expanded treatment options when primary therapies are ineffective. The research team intends to work with international clinical networks to speed up biomarker screening protocols. Validating miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor treatments during early intervention stages.